Most US Food & Drug Administration review teams should be able to meet user fee deadlines in the near term amid changing work patterns prompted by the COVID-19 outbreak, although review divisions that are central to addressing the crisis – including antiviral, critical care and pulmonary – may need to prioritize their workloads, Center for Drug Evaluation & Research Director Janet Woodcock told the Pink Sheet.
“So far, it seems like people are being able to get their work done,” Woodcock said in a podcast interview....






